Document is current
Any future updates will be listed below
-
Authors
Guo, Qingyi
Zhang, Chaoqi
Wang, Bo
Iriguchi, Shoichi
Ishikawa, Akihiro
Minagawa, Atsutaka
Ishii, Tomoko
Kawai, Yohei
Kaneko, Shin https://orcid.org/0000-0003-2291-4586
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (22H00586)
Japan Science and Technology Corporation (JPMJSP2110)
Shinobi therapeutics
- License Information
-
More Information
Article History
Received: 5 October 2025
Accepted: 5 December 2025
First Online: 3 January 2026
Declarations
:
: The studies involving humans were approved by Kyoto University School of Medicine Ethics Committee (approval no. G590). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
: Not applicable.
: S.K. is a founder, shareholder, and director of Shinobi Therapeutics Inc. S.K. has also received research funding from Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., Panasonic Corporation, Mitsui-soko Co., Ltd., KOTAI Biotechnologies, and Shinobi Therapeutics Inc.
